Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Items 501–600 of 1,000
Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1
Ribeiro, T., Abad, A., & Feldman, B. M. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12212 · Cited by 33
Gene therapy for hemophilia: Progress to date and challenges moving forward
Gollomp, K. L., Doshi, B. S., & Arruda, V. R. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.08.012 · Cited by 33
Treatment Options in Hemophilia
Miesbach, W., Schwäble, J., Müller, M. M., & Seifried, E. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0791 · Cited by 39
Dover, S., Blanchette, V. S., Wrathall, D., Pullenayegum, E., Kazandjian, D., Song, B., Hawes, S. A., Cloutier, S., RIVARD, G. ‐., Klaassen, R. J., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12301 · Cited by 29
Santagostino, E., Kenet, G., Fischer, K., Biss, T. T., Ahuja, S. P., & Steele, M. (2020) · Haemophilia · doi:10.1111/hae.13963 · Cited by 30
Chowdary, P., Fischer, K., Collins, P. W., Cotterill, A., Konkle, B. A., Blanchette, V. S., Pipe, S. W., Berntorp, E. E., Wolfsegger, M. J., Engl, W., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1709519 · Cited by 30
Personalising haemophilia management with shared decision making
Valentino, L. A., Blanchette, V. S., Négrier, C., O’Mahony, B., Bias, V., Sannié, T., & Skinner, M. W. (2021) · The Journal of Haemophilia Practice · doi:10.17225/jhp00178 · Cited by 31
Self-citationBakeer, N., Dover, S., Babyn, P., Feldman, B. M., von Drygalski, A., Doria, A. S., Ignas, D. M., Abad, A., Bailey, C., Beggs, I., et al. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12531 · Cited by 30
Self-citationMeeting the challenges of haemophilia care and patient support in China and Brazil
Ozelo, M. C., Matta, M. A. P., & Yang, R. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02890.x · Cited by 30
Mancuso, M. E., Berardinelli, L., Beretta, C., Raiteri, M., Pozzoli, E., & Santagostino, E. (2009) · Haematologica · doi:10.3324/haematol.2008.001594 · Cited by 30
“Prophylaxis 11 602 14 4 (367-1,537) (9-16) (2-8.”
BackgroundMancuso, M. E., Mannucci, P. M., Sartori, A., Agliardi, A., & Santagostino, E. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07087.x · Cited by 30
Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin
Sherman, A., Byrne, B. J., Markusic, D. M., Jiang, H., Biswas, M., Rogers, G. L., & Herzog, R. W. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-05-0404 · Cited by 31
“Current treatment for HA involves the administration of recombinant or plasma-derived FVIII protein, either prophylactically or on-demand following a bleeding event (1, 2).”
BackgroundInfluentialProphylactic versus on-demand treatments for hemophilia: advantages and drawbacks
Castaman, G., & Linari, S. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1486704 · Cited by 30
Importance of pharmacokinetics in the management of hemophilia
Barnes, C. D. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24339 · Cited by 29
“Use of prophylaxis in hemophilia is now considered standard of care in many developed countries and recent trials have highlighted the benefit of prophylaxis versus on demand therapy in preventing hemophilia related joint damage [1].”
BackgroundGene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation
Scott, D. W., & Lozier, J. N. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08925.x · Cited by 34
“Further, inhibitors prevent prophylactic factor administration, which is shown to prevent chronic haemarthopathy (Manco-Johnson et al, 2007).”
BackgroundInfluentialShort-term and mid-term outcome of total ankle replacement in haemophilic patients
Asencio, J.-G., Leonardi, C., Biron‐Andréani, C., & Schved, J. (2014) · Foot and Ankle Surgery · doi:10.1016/j.fas.2014.08.004 · Cited by 29
“The current standard treatment for patients with painful, progressive arthropathy is tibio-talar arthrodesis [10–13], which demonstrates good results in terms of pain and bleeding episodes but with loss of mobility [13].”
BackgroundMethodMiners, A. H. (2012) · Haemophilia · doi:10.1111/hae.12009 · Cited by 31
Négrier, C., Young, G. A., Karim, F. A., Collins, P. W., Hanabusa, H., Colberg, T., Goldman, B., Walsh, C. E., & the paradigm 2 and 4 Investigators (2016) · Haemophilia · doi:10.1111/hae.12902 · Cited by 29
Seuser, A., Kurnik, K., & Mahlein, A. (2018) · Sensors · doi:10.3390/s18020518 · Cited by 29
“The results in literature implicate, that silent bleeds occur [2,5].”
BackgroundEmicizumab should be prescribed independent of immune tolerance induction
Quellec, S. L., & Négrier, C. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018015859 · Cited by 29
Shah, A., Solms, A., Wiegmann, S., Ahsman, M. J., Berntorp, E. E., Tiede, A., Iorio, A., Mancuso, M. E., Zhivkov, T., & Lissitchkov, T. J. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03747-2 · Cited by 29
B cell–activating factor modulates the factor VIII immune response in hemophilia A
Doshi, B. S., Rana, J., Castaman, G., Shaheen, M. A., Kaczmarek, R., Butterfield, J. S. S., Meeks, S. L., Leissinger, C., Biswas, M., & Arruda, V. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142906 · Cited by 33
“Prophylactic FVIII replacement therapy prevents bleeding-related morbidity and mortality (3), but the formation of anti-FVIII ( α -FVIII) neutralizing alloantibodies, termed inhibitors, represents the most significant therapeutic complication.”
Self-citationMason, J. A., & Young, G. A. (2021) · Haemophilia · doi:10.1111/hae.14353 · Cited by 29
Non‐factor therapies for bleeding disorders: A primer for the general haematologist
Swan, D., Mahlangu, J. N., & Thachil, J. V. (2022) · eJHaem · doi:10.1002/jha2.442 · Cited by 30
Gene therapy for hemophilia—opportunities and risks
Miesbach, W., Klamroth, R., Oldenburg, J., & Tiede, A. (2022) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2022.0353 · Cited by 47
Major differences in bleeding symptoms between factor VII deficiency and hemophilia B
Bernardi, F., Dolce, A., Pinotti, M., Shapiro, A. D., Santagostino, E., Peyvandi, F., Bátorová, A., Lapecorella, M., Schved, J., Ingerslev, J., et al. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03329.x · Cited by 29
Self-citationCallan, M. B., Haskins, M. E., Wang, P., Zhou, S., High, K. A., & Arruda, V. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151800 · Cited by 30
“This therapeutic strategy is often recommended for boys around 2 years of age or after the first episode of bleeding [2,3] and more recently, throughout adult life [4].”
BackgroundChang, C., Li, T., Cheng, S., Pan, R. ‐., Wang, H., Lin, S., & Chen, Y. (2016) · Haemophilia · doi:10.1111/hae.13117 · Cited by 29
Chowdary, P. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.12.012 · Cited by 31
Outcome measures monitoring physical function in children with haemophilia: a systematic review
Stephensen, D., Drechsler, W. I., & Scott, O. M. (2013) · Haemophilia · doi:10.1111/hae.12299 · Cited by 28
Carneiro, J. D. A., Blanchette, V. S., Ozelo, M. C., Antunes, S. V., Villaça, P. R., Young, N. L., Castro, D. A., Brandão, L. R., Carcao, M. D., Abad, A., et al. (2017) · Haemophilia · doi:10.1111/hae.13230 · Cited by 28
Inhibitor clinical burden of disease: a comparative analysis of the CHESS data
Oladapo, A. O., Lü, M., Walsh, S. V., O’Hara, J., & Kauf, T. L. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0929-9 · Cited by 28
Solms, A., Shah, A., Berntorp, E. E., Tiede, A., Iorio, A., Linardi, C. C. G., Ahsman, M. J., Mancuso, M. E., Zhivkov, T., & Lissitchkov, T. J. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04280-3 · Cited by 28
SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders
Cnossen, M. H., van Moort, I., Reitsma, S. H., de Maat, M. P. M., Schutgens, R. E. G., Urbanus, R. T., Lingsma, H. F., Mathôt, R. A. A., Gouw, S. C., Meijer, K., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15778 · Cited by 28
“, health insurerd) are better able to control costs with reduction of risks, (4) suppliers can align prices with patient outcomes, and (5) society as a whole becomes healthier while reducing overall health- care spending.”
BackgroundByams, V. R., Baker, J., Bailey, C., Connell, N. T., Creary, M., Curtis, R., Dinno, A., Guelcher, C., Kim, M. H., Kulkarni, R., et al. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2183836 · Cited by 30
“Clinical research has improved diagnostic precision [5], management of musculoskeletal sequelae of bleeding episodes [6–8], and prevention and treatment of morbidities caused by virally (e.g. HIV and hepatitis) contaminated therapies [9,10].”
Stephensen, D., Drechsler, W. I., & Scott, O. M. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02705.x · Cited by 28
Kashiwakura, Y., Ohmori, T., Mimuro, J., Yasumoto, A., Ishiwata, A., Sakata, A., Madoiwa, S., Inoue, M., Hasegawa, M., OZAWA, K., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04851.x · Cited by 29
Insurance, Home Therapy, and Prophylaxis in U.S. Youth with Severe Hemophilia
Baker, J., Riske, B., Voutsis, M., Cutter, S., & Presley, R. J. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.09.002 · Cited by 27
Self-citationProphylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors
Ewing, N. P., Escuriola‐Ettingshausen, C., & Kreuz, W. (2015) · Haemophilia · doi:10.1111/hae.12602 · Cited by 28
Ferreira, A., Bustamante-Teixeira, M. T., Leite, I. C. G., Corrêa, C. S. L., Rodrigues, D. D. O. W., & da Cruz, D. T. (2013) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20130010 · Cited by 28
“Infusions can be administered as prophylaxis, preventing bleeding episodes and reducing the incidence of arthropathies(7-10), or on demand, i.”
BackgroundManco‐Johnson, M. J., Sanders, J. S., Ewing, N. P., Rodriguez, N. I., Tarantino, M. D., Humphries, T. J., & TEEN/TWEN Study Group (2013) · Haemophilia · doi:10.1111/hae.12177 · Cited by 28
Self-citationPotential role of a new PEGylated recombinant factor VIII for hemophilia A
Wynn, T., & Gümüşçü, B. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s82457 · Cited by 30
“With the availability of plasma-derived and recombinant FVIII products, the benefits of primary prophylaxis were demonstrated and they became the standard of care for patients with severe factor deficiencies.(8,9) The widespread use of prophylactic regimens has improved joint outcome and increased quality of life,(9,1…”
Oldenburg, J., Zimmermann, R., Κατσαρού, Ό., Zanon, E., Kellermann, E., Lundin, B., & Ellinghaus, P. (2016) · Haemophilia · doi:10.1111/hae.12936 · Cited by 28
Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice
Tischer, B., Marino, R., & Napolitano, M. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s151812 · Cited by 28
Seuser, A., Khayat, C. D., Négrier, C., Sabbour, A., & Heijnen, L. (2018) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000767 · Cited by 34
Prophylaxis for adults with haemophilia: one size does not fit all.
Fischer, K. (2012) · Europe PMC (PubMed Central) · doi:10.2450/2012.0174-11 · Cited by 28
Haemophilia B is clinically less severe than haemophilia A: further evidence.
Franchini, M., & Mannucci, P. M. (2018) · Blood transfusion · doi:10.2450/2016.0158-16 · Cited by 28
Hua, B., Lian, X., Li, K., Lee, A., Poon, M., & Zhao, Y. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000389 · Cited by 27
Lissitchkov, T. J., Klukowska, A., Pasi, J., Kessler, C. M., Klamroth, R., Liesner, R. J., Belyanskaya, L. L., Walter, O., Knaub, S., Bichler, J., et al. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719858471 · Cited by 28
Lalezari, S., Reding, M. T., Pabinger, I., Holme, P. A., Négrier, C., Chalasani, P., Shin, H., Wang, M., Tseneklidou‐Stoeter, D., & Enriquez, M. M. (2019) · Haemophilia · doi:10.1111/hae.13853 · Cited by 27
Ankle arthritis – an important signpost in rheumatologic practice
Kiely, P. D. W., & Lloyd, M. E. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa531 · Cited by 27
Croteau, S. E., Cook, K., Sheikh, L., Chawla, A., Sammon, J., Solari, P. G., Kim, B. B., Hinds, D. R., & Thornburg, C. D. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.3.316 · Cited by 27
Mancuso, M. E., Holstein, K., O’Donnell, J. S., Lobet, S., Klamroth, R., & the FVIII Think Tank Study Group (2023) · Haemophilia · doi:10.1111/hae.14734 · Cited by 29
Haemophilia Utilization Group Study – Part Va (HUGS Va): design, methods and baseline data
Zhou, Z., Wu, J., Baker, J., Curtis, R., Forsberg, A. D., Huszti, H. C., Koerper, M. A., LOU, M., Miller, R., Parish, K. L., et al. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02595.x · Cited by 28
Self-citationBrodin, E., Sunnerhagen, K. S., Baghaei, F., & Törnbom, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139690 · Cited by 31
Hemophilic arthropathy of the elbow: prophylaxis, imaging, and the role of invasive management
Dale, T. M., Saucedo, J. M., & Rodriguez-Merchan, E. C. (2015) · Journal of Shoulder and Elbow Surgery · doi:10.1016/j.jse.2015.06.018 · Cited by 27
Biophysical characterisation of GlycoPEGylated recombinant human factor VIIa
Plesner, B., Westh, P., & Nielsen, A. D. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.034 · Cited by 27
Ragni, M. V., Journeycake, J. M., & Brambilla, D. J. (2007) · Haemophilia · doi:10.1111/j.1365-2516.2007.01599.x · Cited by 27
Ducore, J. M., Miguelino, M. G., & Powell, J. S. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.951322 · Cited by 30
Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization
Kis‐Tóth, K., Rajani, G. M., Simpson, A., Henry, K. L., Dumont, J., Peters, R., Salas, J., & Loh, C. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024497 · Cited by 28
Blood-Induced Arthropathy: A Major Disabling Complication of Haemophilia
Leuci, A., & Dargaud, Y. G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010225 · Cited by 29
Castaman, G. (2008) · PubMed Central · doi:10.2450/2008.0036-08 · Cited by 26
Inhibitors: our greatest challenge. Can we minimize the incidence?
Kruse‐Jarres, R. (2012) · Haemophilia · doi:10.1111/hae.12049 · Cited by 26
Poonnoose, P. M., Carneiro, J. D. A., Cruickshank, A.-L., Ekiaby, M. E., Bianco, R. P., Ozelo, M. C., de Bosch, N., Baghaipour, M. R., Tien, S. L., Chuansumrit, A., et al. (2017) · Haemophilia · doi:10.1111/hae.13242 · Cited by 26
Trakymienė, S. Š., Economou, M. P., Kenet, G., Landorph, A., Shen, C., & Kearney, S. L. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15036 · Cited by 26
“8 (10) 3 (4) 1 (1) 0 (0) Time (months) 12 0 16”
Gene Therapy for Inherited Bleeding Disorders
Arruda, V. R., Weber, J., & Samelson‐Jones, B. J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1722862 · Cited by 25
Present and future challanges in the treatment of haemophilia: a clinician's perspective.
Mannucci, P. M., & Franchini, M. (2013) · Europe PMC (PubMed Central) · doi:10.2450/2013.012s · Cited by 26
Gringeri, A., Wolfsegger, M. J., Steinitz, K. N., & Reininger, A. J. (2015) · Haemophilia · doi:10.1111/hae.12605 · Cited by 27
Tertiary prophylaxis in adults: is there a rationale?
Gringeri, A., Lambert, T., Street, A., & Aledort, L. M. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02843.x · Cited by 26
Factor VIII therapy for hemophilia A: current and future issues
Aledort, L. M., Ljung, R. C. R., Mann, K. G., & Pipe, S. W. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.899896 · Cited by 26
“On-demand therapy decreases morbidity and mortality in patients with hemophilia but does not prevent the development of arthropathy [93,94] In contrast, prophylactic infusions of FVIII, aimed at converting severe hemophilia to the moderate subtype (FVIII 1–4%) [95]), can protect against joint bleeding and subsequent j…”
BackgroundMethodInfluentialCarvalhosa, A. M. B. E., Henrard, S., Lambert, C., & Hermans, C. R. J. R. (2013) · Haemophilia · doi:10.1111/hae.12341 · Cited by 26
FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations
Perry, D. J., Berntorp, E. E., Tait, R. C., Dolan, G., Holme, P. A., Laffan, M., Lassila, R., Mumford, A. D., Pasi, J., Wilde, J., et al. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02104.x · Cited by 26
Titapiwatanakun, R., MOIR, C., Pruthi, R. K., Stavlo, P. L., Schmidt, K. A., & Rodriguez, V. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01906.x · Cited by 26
Usuba, K., Price, V. E., Blanchette, V. S., Abad, A., Altisent, C., Buchner‐Daley, L., Carneiro, J. D. A., Feldman, B. M., Fischer, K., Grainger, J., et al. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12202 · Cited by 26
Impact of an Individualized Prophylaxis Approach on Young Adults with Severe Hemophilia
Carvalho, M., Lopes, M., Araújo, F., & Fernandes, S. (2014) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0034-1394109 · Cited by 25
Kruse‐Jarres, R. (2011) · Hematology · doi:10.1182/asheducation-2011.1.407 · Cited by 25
Efmoroctocog Alfa: A Review in Haemophilia A
Frampton, J. E. (2016) · Drugs · doi:10.1007/s40265-016-0622-z · Cited by 31
Rodriguez-Merchan, E. C. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100642 · Cited by 25
Hemophilia gene therapy—New country initiatives
Reiss, U. M., Zhang, L., & Ohmori, T. (2020) · Haemophilia · doi:10.1111/hae.14080 · Cited by 54
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
Garrison, L. P., Pezalla, E., Towse, A., Yang, H., Faust, E., Wu, E. Q., Li, N., Sawyer, E. K., & Recht, M. (2021) · Value in Health · doi:10.1016/j.jval.2021.05.008 · Cited by 27
Self-citationHang, M., Blanchette, V. S., Pullenayegum, E., McLimont, M., & Feldman, B. M. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04228.x · Cited by 25
Longer‐acting clotting factor concentrates for hemophilia
Powell, J. S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12912 · Cited by 25
Hypercalciuria in children with haemophilia suggests primary skeletal pathology
Ranta, S., Viljakainen, H. T., Mäkipernaa, A., & Mäkitie, O. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08639.x · Cited by 25
Factor VIII/factor IX prophylaxis for severe hemophilia
Carcao, M. D., & Srivastava, A. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.10.006 · Cited by 25
“Fulldose prophylaxis regimens have been shown to reduce annual joint bleeding rates (AJBR) to well below 1 [4,24].”
BackgroundInfluentialFc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
Mannucci, P. M., & Mancuso, M. E. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s47312 · Cited by 30
“Prophylaxis of bleeds, involving the regular infusion of plasma-derived or recombinant pharmaceutical products containing the deficient coagulation factor, is the mainstay of hemophilia care, made evidence-based by the results of two randomized clinical trials that showed the capacity of this therapeutic approach to a…”
Manners, P. J., Price, P., Buurman, D., Lewin, B., Smith, B., & Cole, C. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141236 · Cited by 25
“Prophylaxis has been recommended since the publication by Manco-Johnson, et al in 2007 of a randomized trial of prophylaxis compared with episodic treatment, along with other similar trials 5,6,7,8,9,10 .”
Resultvan Herrewegen, F., Meijers, J. C. M., Peters, M., & van Ommen, C. H. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1571-x · Cited by 25
“To prevent joint bleedings and thus arthropathy in patients with severe hemophilia, prophylactic treatment with clotting factor concentrate is mostly indicated [13].”
Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII
Marcos-Contreras, O. A., Smith, S. M., Bellinger, D. A., Raymer, R. A., Merricks, E. P., Faella, A., Pavani, G., Zhou, S., Nichols, T. C., High, K. A., et al. (2015) · Blood · doi:10.1182/blood-2015-09-671420 · Cited by 26
“In the case of hemophilia, early prophylaxis has demonstrated added clinical benefits comparedwith on-demand therapy.(29,30) Specifically, for FVII deficiency, and based on limited data, early prophylaxis with rhFVIIa is recommended.”
BackgroundChowdary, P., Fosbury, E., Riddell, A. F., & Mathias, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s80814 · Cited by 27
“Previous studies had compared results of prophylaxis against historical controls, but in 2007 the results of an American multicenter, randomized, open-label trial were published in which boys were enrolled from 1996 onwards.(23) Boys were randomly assigned either prophylaxis (25 IU/kg on alternate days) or an enhanced…”
McEneny‐King, A., Chelle, P., Henrard, S., Hermans, C. R. J. R., Iorio, A., & Edginton, A. N. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9040047 · Cited by 30
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
“If begun in early childhood, regular prophylactic factor replacement also minimizes cumulative joint damage from hemarthrosis [8, 9].”
BackgroundStephensen, D., Classey, S., Harbidge, H., Patel, V., Taylor, S., & Wells, A. J. (2018) · Haemophilia · doi:10.1111/hae.13440 · Cited by 25
Kearney, S. L., Raffini, L. J., Pham, T. P., Lee, X. Y., Mackensen, S. V., Landorph, A., Takedani, H., & Oldenburg, J. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s196103 · Cited by 25
Gupta, N., Benbouzid, A., Belhani, M. F., Andaloussi, M. E., Maani, K., Wali, Y. A. M. S., Fegoun, S. B. E., Saad, H. A., & Mahlangu, J. N. (2019) · TH Open · doi:10.1055/s-0039-1688414 · Cited by 25
The factor VIII treatment history of non‐severe hemophilia A
Abdi, A., Kloosterman, F. R., Eckhardt, C. L., Male, C., Castaman, G., Fischer, K., Beckers, E. A. M., Kruip, M. J. H. A., Peerlinck, K., Mancuso, M. E., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15076 · Cited by 25
Advances in the clinical management of inhibitors in hemophilia A and B
Leissinger, C. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.10.008 · Cited by 24
Self-citationChristensen, K. R., Kjelgaard-Hansen, M. J., Nielsen, L. N., Wiinberg, B., Althoehn, F. A., Poulsen, N. B., Vøls, K. K., Thyme, A. P., Nordahl, K. M. L., Hansen, A. K., et al. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key186 · Cited by 24
Comparing objective and self‐reported measures of adherence in haemophilia
Guedes, V. G., Corrente, J. E., Farrugia, A., Thomas, S., Wachholz, P. A., & Vidal, E. I. D. O. (2019) · Haemophilia · doi:10.1111/hae.13811 · Cited by 24
The Effectiveness of Tools for Monitoring Hemophilic Arthropathy
Oymak, Y., Yıldırım, A. T., Yaman, Y., Gürçınar, M., Firat, A., Çubukçu, D., Cartı, Ö., Özek, G., & Vergin, R. C. (2014) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000210 · Cited by 24
Berntorp, E. E., Spotts, G. E., Patrone, L., & Ewenstein, B. M. (2014) · Biologics · doi:10.2147/btt.s53456 · Cited by 24
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.